Skip to main content

Dermata Therapeutics Inc (DRMA) Stock

Dermata Therapeutics Inc Stock Details, Movements and Public Alerts

Stock Details

Dermata Therapeutics Inc (DRMA), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $2.40. Over the past 52 weeks, it has ranged between $1.58 and $16.50. This places the current price at 14.5% of its 52-week high and 51.9% above its 52-week low. Recent trading volume was recorded at 101. The 14-day Relative Strength Index (RSI) stands at 47.89, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $2.58 by 6.98%. Similarly, it is below its 200-day moving average of $5.47 by 56.12%. The MACD histogram is 0.04, indicating bullish momentum (MACD Line: -0.15, Signal Line: -0.19). There are currently 3 active alerts set for DRMA by users.

52-Week Range

$16.50 - $1.58

-85.45% from high · +51.90% from low

Avg Daily Volume

2,503,494

20-day average

100-day avg: 631,750

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

0.14

Below market average

Price to Book

1.78

EV/EBITDA

0.58

EPS (TTM)

$15.24

Beta

0.54

Less volatile than market

Q:How is DRMA valued relative to its earnings and growth?
Dermata Therapeutics Inc trades at a P/E ratio of 0.14, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong.
Q:What is DRMA's risk profile compared to the market?
With a beta of 0.54, Dermata Therapeutics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.78 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-7,856,542

Return on Equity

-203.40%

Return on Assets

-96.50%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is DRMA's business model?
Profitability metrics are not available for this stock.
Q:What are DRMA's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$7.0M

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

3.20M

Book Value/Share

$4.69

Asset Type

Common Stock

Q:What is DRMA's market capitalization and position?
Dermata Therapeutics Inc has a market capitalization of $7.0M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 3.20M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does DRMA's price compare to its book value?
Dermata Therapeutics Inc's book value per share is $4.69, while the current stock price is $2.40, resulting in a price-to-book (P/B) ratio of 0.51. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$10.00

316.67% upside potential

Analyst Recommendations

No analyst ratings available

Q:How reliable are analyst predictions for DRMA?
0 analysts cover DRMA with 0% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $10.00 implies 316.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on DRMA?
Current analyst recommendations:The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 16, 2026, 02:04 AM

Technical Indicators

RSI (14-day)

47.89

Neutral

50-Day Moving Average

$2.58

-6.98% below MA-50

200-Day Moving Average

$5.47

-56.12% below MA-200

MACD Line

-0.15

MACD Signal

-0.19

MACD Histogram

0.04

Bullish

Q:What does DRMA's RSI value tell investors?
The RSI (Relative Strength Index) for DRMA is currently 47.89, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret DRMA's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.15 above the signal line at -0.19, with histogram at 0.04. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($2.58) is below the 200-day MA ($5.47), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Jan 16, 2026, 11:26 AM

Active Alerts

Alert Condition
Price falls below
Threshold
$1.58
Created
Jan 6, 2026, 05:22 PM
Alert Condition
RSI Threshold Cross
Threshold
30
Created
Jan 5, 2026, 05:26 PM
Alert Condition
Golden Cross
Threshold
N/A
Created
Dec 31, 2025, 05:15 AM

Stay Ahead of the Market with Dermata Therapeutics Inc Alerts

Set up price alerts for Dermata Therapeutics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.